VIVS

VivoSim Labs Inc

May 15 • 04:00PM ET

1.29

-0.03 -2.27 %

Healthcare • Biotechnology • USA • Nano • NASD

Index	-	P/E	2.77	EPS (ttm)	0.47	Insider Own	12.67%	Shs Outstand	2.61M	Perf Week	-7.19%
Market Cap	3.36M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	2.28M	Perf Month	-14.00%
Enterprise Value	-0.12M	PEG	-	EPS next Q	-	Inst Own	3.76%	Short Float	2.32%	Perf Quarter	-35.50%
Income	-1.23M	P/S	24.00	EPS this Y	-	Inst Trans	-15.03%	Short Ratio	0.67	Perf Half Y	-42.92%
Sales	0.14M	P/B	0.76	EPS next Y	-	ROA	-22.71%	Short Interest	0.05M	Perf YTD	-28.73%
Book/sh	1.70	P/C	0.78	EPS next 5Y	-	ROE	-51.07%	52W High	5.30 -75.66%	Perf Year	-33.16%
Cash/sh	1.65	P/FCF	-	EPS past 3/5Y	52.42% 45.28%	ROIC	-27.36%	52W Low	1.25 3.20%	Perf 3Y	-94.19%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-54.21% -42.01%	Gross Margin	-64.08%	Volatility	4.54% 7.75%	Perf 5Y	-98.43%
Dividend TTM	-	EV/Sales	-0.86	EPS Y/Y TTM	104.50%	Oper. Margin	-8066.20%	ATR (14)	0.10	Perf 10Y	-99.78%
Dividend Ex-Date	-	Quick Ratio	2.44	Sales Y/Y TTM	16.39%	Profit Margin	-864.08%	RSI (14)	31.78	Recom	3.00
Dividend Gr. 3/5Y	- -	Current Ratio	2.44	EPS Q/Q	54.96%	SMA20	-9.03%	Beta	1.40	Target Price	64.80
Payout	-	Debt/Eq	0.18	Sales Q/Q	8.33%	SMA50	-17.62%	Rel Volume	0.15	Prev Close	1.32
Employees	13	LT Debt/Eq	0.01	Earnings	-	SMA200	-40.03%	Avg Volume	79.30K	Price	1.29
IPO	Feb 14, 2012	Option/Short	No / Yes	EPS/Sales Surpr.	46.15% -26.83%	Trades		Volume	11,621	Change	-2.27%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-13-18	Initiated	H.C. Wainwright	Buy	$2.50
Nov-10-17	Downgrade	Raymond James	Outperform → Mkt Perform
Jan-25-17	Initiated	Raymond James	Outperform
Aug-11-15	Downgrade	Cantor Fitzgerald	Buy → Hold
Jun-29-15	Initiated	Piper Jaffray	Overweight	$5
Jun-29-15	Initiated	Jefferies	Buy	$5

Apr-28-26 08:05AM	VivoSim Platform Predicts Gastrointestinal Toxicity (Diarrhea) in an AI Model Trained on Human Intestinal Model Results - Without Animal Testing (GlobeNewswire)
Apr-01-26 08:05AM	VivoSim Announces Pricing of up to a $4 Million Public Offering (GlobeNewswire) +13.29%
Mar-24-26 08:05AM	VivoSim Releases Antibody Drug Conjugate (ADC) Data Showing Power to Detect ADC Toxicity and Guide Design of Safer ADCs (GlobeNewswire)
Mar-03-26 08:05AM	VivoSim Appoints Arumugham (Ragoo) Raghunathan as Vice President of Global Sales (GlobeNewswire) -12.73%
Feb-11-26 08:05AM	VivoSim to Debut Antibody Drug Conjugate Data, representing a major new market for NAMkind models, at Society of Toxicology Meeting in San Diego (GlobeNewswire)
06:59AM	Loading…
Feb-02-26 06:59AM	NIO January Deliveries Nearly Double Year On Year (GuruFocus.com) -16.78%
Jan-29-26 04:05PM	VivoSim Expands Asia-Pacific Access to NAMKind Human-Based Toxicology Services Through New Distributor Agreement in Korea and China (GlobeNewswire) +71.76%
Jan-06-26 08:05AM	VivoSim Labs Appoints Amar Sethi, M.D., Ph.D. as Chief Scientific Officer (GlobeNewswire)
Jan-02-26 07:03AM	NIO Posts Record December and Q4 Deliveries as 2025 Volumes Surge (GuruFocus.com)
Dec-01-25 10:52AM	Nio Stock Slumps After Surprise November Delivery Drop (GuruFocus.com)
06:25AM	NIO Just Posted a 76% Delivery Surge--Here's What Investors Might Be Missing (GuruFocus.com)
Nov-04-25 07:51AM	NIO Stock Pops as EV Maker Smashes Delivery Record With 92% Surge (GuruFocus.com) -6.78%
Oct-01-25 05:45AM	NIO Stock Soars Past 52-Week High After Record Deliveries (Benzinga) +9.93%
Sep-02-25 05:40AM	NIO, XPeng, Li Auto Log Strong August Deliveries Highlighting China's EV Momentum (Benzinga)
Aug-14-25 08:05AM	VivoSim Labs Appoints Tony Lialin as Chief Commercial Officer (GlobeNewswire)
04:44PM	Loading…
Aug-12-25 04:44PM	VivoSim: Fiscal Q1 Earnings Snapshot (Associated Press Finance) +6.05%
May-13-25 08:05AM	VivoSim's NAMKind Intestine Wins Blue Ribbon Award at Digestive Disease Week Conference (GlobeNewswire)
May-07-25 08:05AM	VivoSim Presents Best-in-Class Liver Toxicology Prediction Results at Digestive Disease Week Conference (GlobeNewswire)
Apr-24-25 08:05AM	VivoSim Announces Emergence from Stealth Mode To Provide Technologies for FDA Turn Away from Animal Models, $10B+ Market (GlobeNewswire) -8.33%
Apr-23-25 08:05AM	VivoSim to Carry Forward Organovo 3D Bioprinting (GlobeNewswire)
Apr-02-25 08:05AM	Organovo Provides Update on Cash and Nasdaq Continued Listing Requirements (GlobeNewswire)
Mar-27-25 08:05AM	Organovo Provides Business Update (GlobeNewswire) -13.50%
Mar-25-25 11:25AM	Organovo Announces Close of the Sale of FXR Program to Eli Lilly and Company (GlobeNewswire) -5.02%
Mar-19-25 08:05AM	Organovo Announces Reverse Stock Split (GlobeNewswire) -32.61%
Mar-11-25 07:00AM	Matinas BioPharma Appoints Seasoned Biotech Leaders to Board of Directors (GlobeNewswire)
Mar-06-25 08:05AM	Organovo Announces the Issuance of Additional Shares in Conjunction with Warrant Exercises (GlobeNewswire)
Feb-25-25 08:05AM	Organovo's FXR Program, including FXR314, to Be Acquired by Eli Lilly and Company (GlobeNewswire) +244.17%
Feb-19-25 09:17AM	Organovo: Fiscal Q3 Earnings Snapshot (Associated Press Finance)
Jan-06-25 08:05AM	Organovo Announces Appointment of Norman Staskey as Chief Financial Officer (GlobeNewswire) +7.15%
Nov-20-24 08:05AM	Organovo Presents Clinical Data of FXR314 in Phase 2 MASH in an Oral Presentation at The Liver Meeting (GlobeNewswire)
08:06AM	Loading…
Nov-13-24 08:06AM	Organovo to Present Clinical Data of FXR314 in Phase 2 MASH in an Oral Presentation at The Liver Meeting Sponsored by the American Association for the Study of Liver Diseases (GlobeNewswire)
Nov-08-24 04:15PM	Organovo: Fiscal Q2 Earnings Snapshot (Associated Press Finance) -6.60%
Jul-16-24 08:05AM	Organovo Highlights FXR314 Near Term Value Catalysts at Jones Trading Conference Strong Preclinical and Human Rationale for FXR314 in P2 2 Ulcerative Colitis (GlobeNewswire) -8.55%
Jun-03-24 11:52AM	ONVO Stock Earnings: Organovo Holdings Beats EPS, Misses Revenue for Q4 2024 (InvestorPlace) +5.78%
May-21-24 08:05AM	Organovo Data Presented at Digestive Disease Week (DDW2024) Demonstrating Potential for FXR314 as Combination Therapy with Tofacitinib for Inflammatory Bowel Disease (GlobeNewswire)
May-14-24 11:00AM	Organovo to Present Data on FXR314 at Digestive Diseases Week (DDW2024) (GlobeNewswire)
May-09-24 07:29AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday (InvestorPlace)
May-08-24 08:00PM	Organovo Holdings, Inc. Announces Pricing of $5.25 Million Public Offering (GlobeNewswire) +5.49%
Apr-15-24 08:13AM	Organovo's fatty liver disease drug meets main goal in mid-stage study (Reuters) +33.65%
08:05AM	Organovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo (GlobeNewswire)
Mar-28-24 08:32PM	Top 15 3D Printing Companies in the US (Insider Monkey)
Feb-08-24 05:52PM	Organovo: Fiscal Q3 Earnings Snapshot (Associated Press Finance) -10.00%
Jan-25-24 08:05AM	Organovo Presents FXR314 3D Human Tissue Model Findings That Show Improved Epithelial Barrier Function and Fibrosis Reduction at Crohn's and Colitis Congress (GlobeNewswire)
Jan-09-24 08:05AM	Organovo To Present FXR314 IBD 3D Model Findings at Upcoming Crohn's and Colitis Congress (GlobeNewswire)
Dec-06-23 08:05AM	Organovo Provides Timing for Release of FXR314 Phase 2 NASH Results (GlobeNewswire) -6.04%
Nov-13-23 08:05AM	CORRECTION Organovo Highlights FXR314 Combination Therapy Potential and Plan (GlobeNewswire) +5.93%
Nov-10-23 05:08AM	Organovo: Fiscal Q2 Earnings Snapshot (Associated Press Finance) -7.53%
Nov-08-23 08:05AM	Organovo Highlights FXR314 Combination Therapy Potential and Plan (GlobeNewswire) -5.18%
Oct-10-23 07:18AM	ONVO: A Company With Great Technology to Impact Health Care (Zacks)
Sep-08-23 12:46PM	Organovo to Participate in the H.C. Wainwright Global Investment Conference (GlobeNewswire)
Aug-25-23 07:36PM	Is Organovo Holdings (ONVO) Too Good to Be True? A Comprehensive Analysis of a Potential Value Trap (GuruFocus.com) -13.16%
Aug-23-23 08:05AM	Organovo Advances Clinical Timelines for FXR314 and Provides Updates on NASH Phase 2 Data (GlobeNewswire) +5.43%
Jul-12-23 03:01AM	Net Asset Value(s) (Business Wire)
May-25-23 10:49AM	Cathie Wood is Selling These 12 Stocks in 2023 (Insider Monkey)
Mar-21-23 08:05AM	Organovo Announces FXR Program (GlobeNewswire)
Feb-10-23 05:12AM	Will Organovo Holdings (NASDAQ:ONVO) Spend Its Cash Wisely? (Simply Wall St.) -17.86%
Nov-15-22 08:05AM	Organovo Announces Target Validation Ahead of Schedule, Accelerating Timeline for First Crohns Disease Drug Candidates (GlobeNewswire)
Sep-06-22 08:20AM	Organovo to Participate in the H.C. Wainwright 24th Annual Global Investment Conference (GlobeNewswire) +13.42%
08:05AM	Organovo Announces Postponement of Annual Meeting of Stockholders (GlobeNewswire)
Jul-08-22 08:05AM	We're Not Very Worried About Organovo Holdings' (NASDAQ:ONVO) Cash Burn Rate (Simply Wall St.) +29.17%
May-17-22 08:05AM	Organovo Achieves 3D Tissue Model for Crohns Disease (GlobeNewswire) +5.86%
Mar-03-22 10:13PM	Why Organovo Holdings, Inc. Stock Soared 49.7% This Week (Motley Fool) -11.34%
Mar-01-22 08:05AM	UPDATE -- Organovo and BICO (CELLINK) Reach Licensing Agreement on Bioprinting Patents (GlobeNewswire) +5.90%
Feb-23-22 08:05AM	Organovo and BICO (CELLINK) Reach Licensing Agreement on Bioprinting Patents (GlobeNewswire) +5.47%
Feb-18-22 04:00PM	Organovo Holdings, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
01:00PM	Organovo Welcomes New Sr. Vice President of Strategy and Business Development (GlobeNewswire)
Feb-12-22 02:09PM	10 3D Printing Companies to Watch in 2022 (Insider Monkey)
Feb-04-22 10:11AM	Cathie Wood Targets Illiquid Assets and Limits Exits in New Fund (Bloomberg)
Feb-02-22 12:00PM	Organovo Guides on Patent Portfolio and Successful IPR Defense of Two Patents (GlobeNewswire)
Jan-21-22 11:37AM	15 Worst Stock Picks of Cathie Wood (Insider Monkey)
Jan-10-22 12:00PM	Organovo Files Counterclaims In Patent Lawsuit Brought Against It by CellInk (GlobeNewswire)
Dec-30-21 09:24AM	Here's Why We're Not Too Worried About Organovo Holdings' (NASDAQ:ONVO) Cash Burn Situation (Simply Wall St.)
Nov-30-21 08:05AM	Organovo On Track to Establish Human 3D Disease Model in Inflammatory Bowel Disease in 2022 (GlobeNewswire)
Sep-17-21 04:10PM	Organovo Announces Adjournment of Annual Meeting of Shareholders Due to Lack of Quorum (GlobeNewswire) -7.57%
Jun-22-21 10:17AM	/C O R R E C T I O N from Source -- RBC Global Asset Management Inc./ (PR Newswire) +5.02%
Jun-15-21 11:38AM	Is Organovo Holdings Inc (ONVO) A Good Stock To Buy? (Insider Monkey)
Mar-02-21 08:05AM	Organovo Announces Participation at the H.C. Wainwright Global Life Sciences Conference March 9-10 2021 (VIRTUAL CONFERENCE) (GlobeNewswire)
Feb-07-21 09:19AM	15 Biggest 3D Companies in the World (Insider Monkey)
Sep-03-20 04:05PM	Organovo Regains Compliance with Nasdaq Minimum Bid Price Requirement (GlobeNewswire) -5.75% -11.54%
Aug-17-20 08:05AM	Organovo Announces One-for-Twenty Reverse Stock Split (GlobeNewswire) -13.52%
Jun-10-20 03:43PM	Hedge Fund Sentiment Is Stagnant On Organovo Holdings Inc (ONVO) (Insider Monkey) -7.54%
Apr-08-20 10:32AM	Edited Transcript of ONVO earnings conference call or presentation 9-Nov-17 10:00pm GMT (Thomson Reuters StreetEvents) +13.63%
07:53AM	The Daily Biotech Pulse: Genmark Pre-Announces Q1 Outperformance, Sage to Eliminate 53% of Workforce, Keros IPO (Benzinga)
Apr-07-20 04:12PM	Organovo Announces Termination of Merger Agreement with Tarveda Therapeutics (Business Wire)
Apr-02-20 08:00AM	Organovo Holdings Founder Calls on Board of Directors to Accept Stockholders Opposition to the Illogical Merger With Tarveda Therapeutics (GlobeNewswire) -13.19%
Mar-31-20 06:30PM	Organovo Holdings, Inc. Reminds Stockholders About Adjourned Special Meeting of Stockholders (Business Wire) +43.36% -28.07%
03:25PM	Viscient Biosciences Will Bioprint 3D Lung Tissue to Aid Pandemic Research, and Viscient Founder Calls for Pause in Organovo Merger Attempt (GlobeNewswire)
Mar-28-20 02:27PM	How 3D-printing is playing a role in coronavirus testing (Yahoo Finance)
Mar-27-20 04:05PM	Organovo Holdings, Inc. Announces Adjournment of Special Meeting of Stockholders (Business Wire)
Mar-23-20 03:30PM	Organovo Holdings Founder Issues Letter Regarding Alternative Paths to Illogical Merger With Tarveda Therapeutics to Stockholders (GlobeNewswire) -10.80%
Mar-19-20 02:36PM	Organovo Founder Issues Letter to Stockholders Regarding Major Missteps and Misjudgment of the Companys Board of Directors (GlobeNewswire) +20.48%
Feb-26-20 08:30AM	Organovo Files Definitive Proxy Statement and Sends Letter to Stockholders (Business Wire) -9.67%
Jan-21-20 07:00AM	The Case Against Tarveda: An Open Letter to Organovo Shareholders (Business Wire) -11.92%
Jan-07-20 08:00AM	An Open Letter to Organovo Shareholders: Organovo Founder Sees Continued Success in Bioprinting (Business Wire) +8.60%
Dec-17-19 07:03PM	Is Organovo Holdings Inc (ONVO) A Good Stock To Buy? (Insider Monkey) -13.11%
Dec-16-19 07:00AM	Organovo and Tarveda Therapeutics Announce Definitive Merger Agreement (Business Wire) +24.12%
Nov-21-19 07:19AM	Will Organovo Continue to Surge Higher? (Zacks) -9.33%
Nov-18-19 09:18AM	Zacks.com featured highlights include: Avinger, Alexion Pharmaceuticals, CyberArk Software, Organovo and Qualys (Zacks)
Nov-15-19 07:06AM	What Bargain Hunting? Tap 5 Stocks With Rising P/E (Zacks) +13.75%
Nov-07-19 10:30AM	Organovo (ONVO) May Report Negative Earnings: Know the Trend Ahead of Q2 Release (Zacks)

VivoSim Labs, Inc. is engaged in the development of bioprinted human tissues that emulate human biology and disease. Its three-dimensional human tissue platform is enabled by its proprietary NovoGen Bioprinters and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company was founded on January 30, 2012 and is headquartered in San Diego, CA.

Executive Chairman & Corporate SecretaryMr. Keith E. Murphy

PresidentMr. Norman Staskey

Ph.D.Dr. Amar A. Sethi M.D.

Chief Commercial OfficerMr. Tony Lialin

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

VIVS

VivoSim Labs Inc

Upgrade your Finviz experience